

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DEL SOLDATO

Atty. Dck. No. 026220-00040

Serial No.: not yet assigned (Divisional of 09/719,164)

Filed: Herewith

For: NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 29, 2003


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- ☒ 4. The references were cited by or submitted to the Office in parent application No. 09/719,164, filed December 12, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these references are not attached. 37 CFR § 1.98(d).

Respectfully submitted,


Hans J. Crosby
Registration No. 44,634

Customer No. 004372
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

HJC/ccd

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

026220-00040

SERIAL NO.

New Div. Appln.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

DEL SOLDATO

FILING DATE

Herewith

GROUP

unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
AB EP 0 759 899 B1	09/15/99	European			xx		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Remington's Pharmaceutical Sciences, Gennaro et al, 15th Ed., 1975
AD	"The Anesthetized Guinea Pig as a Versatile Pharmacological Test Object", Journal of Pharmacological Methods 5, Del Soldato et al, 1981, pp 279-285.
AE	"Pharmacological Characterization of Purinergic Receptors in the Rat Vas Deferens", The Journal of Pharmacology and Experimental Therapeutics, Taylor et al, Vol. 224, No. 1, 1983, pp. 40-45.
AF	"Chronic Inhibition of Nitric Oxide Synthesis - A New Model of Arterial Hypertension", Hypertension, Ribeiro et al, Vol. 20, 1992, pp. 298-303.
AG	"Non-synergistic relaxant effects of vasoactive intestinal polypeptide and SIN-1 in human isolated cavernous artery and corpus cavernosum", European Journal of Pharmacology, Hempelmann et al, Vol. 276, 1995, pp. 277-280.
AH	"Nonpeptide Angiotensin II Receptor Antagonists IV. EXP6155 and EXP6803", Hypertension, Wong et al, Vol. 13, 1989, pp 489-497.
AI	"Action of Beta-Adrenolytics on the Isolated Guinea-Pig Atria", Arch. Int. Pharmacodyn., Grodzinska et al, Vol. 191, 1971, pp. 133-141.
AJ	"Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach", British Journal of Pharmacology, Gretzer et al, Vol. 123, 1998, pp. 927-935.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

026220-00040

SERIAL NO.

New Div. Appln.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

DEL SOLDATO

FILING DATE

Herewith

GROUP

unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	5958926	09-1999	GARVEY et al.			
	AB	5250534	10-1993	BELL et al.			
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
							YES	NO	PART.
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AM	
	AN	
	AO	

EXAMINER

DATE CONSIDERED

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.